New pill aims to slow lung damage in scarring disease
NCT ID NCT06422884
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests an experimental drug called ENV-101 (taladegib) in 213 adults with idiopathic pulmonary fibrosis, a disease that causes lung scarring and makes breathing harder. Participants take either the drug or a placebo daily for several months. The main goal is to see if the drug improves lung function and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENV-101 (taladegib)
What this could lead to
If successful, this could point toward a new treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong
This is a mid-stage trial with 213 participants, so results may not confirm benefit. The drug may cause side effects or fail to improve lung function compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Quilmes, Buenos Aires, B1878FNR, Argentina
-
Research Site
Buenos Aires, 1888, Argentina
-
Research Site
Buenos Aires, C1426ABP, Argentina
-
Research Site
Mendoza, 5501, Argentina
-
Research Site
Mendoza, CP 5500, Argentina
-
Research Site
Camperdown, New South Wales, 2050, Australia
-
Research Site
Macquarie Park, New South Wales, 2109, Australia
-
Research Site
Brisbane, Queensland, 4032, Australia
-
Research Site
South Brisbane, Queensland, 4101, Australia
-
Research Site
Box Hill, Victoria, 3128, Australia
-
Research Site
Nedlands, Western Australia, 6009, Australia
-
Research Site
Graz, Styria, 8036, Austria
-
Research Site
Vienna, 1090, Austria
-
Research Site
Dinant, Namur, 5500, Belgium
-
Research Site
Brussels, 1070, Belgium
-
Research Site
Brussels, 1200, Belgium
-
Research Site
Edmonton, Alberta, T6G 2C8, Canada
-
Research Site
Vancouver, British Columbia, V6Z 2K5, Canada
-
Research Site
Ajax, Ontario, L1S 2J5, Canada
-
Research Site
Montreal, Quebec, H2X 0A9, Canada
-
Research Site
Sherbrooke, Quebec, J1H 5N4, Canada
-
Research Site
Trois-Rivières, Quebec, G8T 7A1, Canada
-
Research Site
Angers, 49933, France
-
Research Site
Bordeaux, 33604, France
-
Research Site
Caen, 14033, France
-
Research Site
Dijon, 21000, France
-
Research Site
Montpellier, 34090, France
-
Research Site
Nantes, 44093, France
-
Research Site
Paris, 75014, France
-
Research Site
Paris, 94270, France
-
Research Site
Rennes, 35033, France
-
Research Site
Tours, 37044, France
-
Research Site
Giessen, Hesse, 35398, Germany
-
Research Site
Immenhausen, Hesse, 34376, Germany
-
Research Site
Hanover, Lower Saxony, 30625, Germany
-
Research Site
Essen, North Rhine-Westphalia, 45239, Germany
-
Research Site
Berlin, 13125, Germany
-
Research Site
Leipzig, 4103, Germany
-
Research Site
Dublin, Leinster, D05 AT88, Ireland
-
Research Site
Dublin, Leinster, D07 A8NN, Ireland
-
Research Site
Cork, Munster, T12 DC4A, Ireland
-
Research Site
Dublin, D04 T6F4, Ireland
-
Research Site
Bologna, Forli-Cesena, 47121, Italy
-
Research Site
Padova, Padua, 35128, Italy
-
Research Site
Florence, Tuscany, 50314, Italy
-
Research Site
Catania, 95123, Italy
-
Research Site
Milan, 20123, Italy
-
Research Site
Turin, 10126, Italy
-
Research Site
Kuala Lumpur, Selangor, 42300, Malaysia
-
Research Site
Kuala Lumpur, Selangor, 50590, Malaysia
-
Research Site
Kuala Lumpur, Selangor, 56000, Malaysia
-
Research Site
Monterrey, Nuevo León, 64060, Mexico
-
Research Site
Monterrey, Nuevo León, 64718, Mexico
-
Research Site
San Nicolás de los Garza, Nuevo León, 66465, Mexico
-
Research Site
San Juan del Río, Querétaro, 76800, Mexico
-
Research Site
Chihuahua City, 31230, Mexico
-
Research Site
Mexico City, 14080, Mexico
-
Research Site
Oaxaca City, 68000, Mexico
-
Research Site
Puebla City, 72180, Mexico
-
Research Site
Auckland, New Zealand
-
Research Site
Christchurch, 8011, New Zealand
-
Research Site
Hamilton, New Zealand
-
Research Site
Seoul, (Deogyang District), 10475, South Korea
-
Research Site
Ulsan, (Dong District), 44033, South Korea
-
Research Site
Busan, (Haeundae District), 48108, South Korea
-
Research Site
Seoul, (Seongbuk District), 02841, South Korea
-
Research Site
Seoul, (Songpa District), 05505, South Korea
-
Research Site
Seoul, (Yongsan District), 04401, South Korea
-
Research Site
Seoul, 16499, South Korea
-
Research Site
Belfast, BT9 7AB, United Kingdom
-
Research Site
Birmingham, B15 2GW, United Kingdom
-
Research Site
Birmingham, B9 5SS, United Kingdom
-
Research Site
Cambridge, CB2 0AY, United Kingdom
-
Research Site
Edinburgh, EH1 3EG, United Kingdom
-
Research Site
Exeter, EX2 5DW, United Kingdom
-
Research Site
Leicester, LE3 9QP, United Kingdom
-
Research Site
London, SW3 6NP, United Kingdom
-
Research Site
Londonderry, BT47 6SB, United Kingdom